Blog Archives

Co-administration of AAV Vectors with SVP-Rapamycin enables vector re-administration in pre-clinical gene therapy

Généthon, founded by the AFM-Téléthon, and Selecta Biosciences, a clinical-stage biopharmaceutical company, today announced that Nature Communications has published their jointly authored paper entitled “Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration”. A world first ! The pre-clinical study led by Genethon demonstrated that co-administration of synthetic vaccine particles encapsulating … [Read more]

Nusinersen is effective in SMA 1 patients older than 7 months

This study, which is part of the Expanded Access Program (EAP; NCT02865109), evaluated the safety and clinical efficacy of nusinersen in 33 children (aged between 8.3 to 113.1 months) with spinal muscular atrophy type 1 (SMA1). Patients were evaluated before treatment initiation (M0) and at 2 months (M2) and 6 months (M6) after treatment initiation. … [Read more]

Role of the neuromuscular junction as a therapeutic target in SMA

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by progressive degeneration of lower motor neurons in the spinal cord, resulting in skeletal muscle atrophy and muscle weakness. Increasing evidence suggests that impaired neuromuscular junction (NMJ) can also be present in SMA. The authors of the present study recently reported the association between … [Read more]

Respiratory evaluation in CMDs and CMs and its relation to clinical trial

Congenital muscular dystrophies (CMDs) and congenital myopathies (CMs) constitute the two most important groups of congenital onset muscle diseases. They represent a heterogeneous group of disorders of the muscle characterized by an early onset of hypotonia and muscle weakness and consequently, a high respiratory morbidity and mortality. The diagnosis and characterization of the weakness of … [Read more]

Institute seminar – October 8th – Luis Garcia (France)

Tricyclo-DNA : Conception d’oligonucléotides antisens pour le traitement de certaines maladies neuromusculaires par modulation d’épissage Monday 8 October 2018 – 12:00-13:00 Pr. Luis GARCIA (Directeur U1179 UVSQ-INSERM, Handicap Neuromusculaire : Physiologie, Biothérapie et Pharmacologie appliquées, UFR des sciences de la santé Simone Veil, Université de Versailles St. Quentin-en-Yvelines, France) Host : Vincent Mouly Institute of Myology auditorium … [Read more]

Potential pathogenic role of anti-SRP and anti-HMGCR antibodies in IMNM

Idiopathic inflammatory myopathies (IIM) are a group of acquired autoimmune disorders that mainly affect the skeletal muscle tissue. Classification criteria of IIM are comprised of polymyositis, dermatomyositis, inclusion body myositis and immune-mediated necrotizing myopathies. One important hallmark of autoimmune diseases is the detection of autoantibodies in patient sera. The anti-SRP (signal recognition particle) and anti-HMGCR … [Read more]

Release of the 69th newsletter from the Institute

After a long break for the summer holidays, welcome to the latest issue of our newsletter!   The Great Family Celebration was an opportunity to look back on 60 years of struggles and victories, and to celebrate advances in research, rights and support for the patients. The kick-off of the Telethon 2018 has also been … [Read more]

Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome

This case report describes an 18-year-old man with a history of intellectual disability, dysmorphic features diabetes mellitus type 1, and thyroiditis related to an 18p deletion (18p-) syndrome. He developed progressive left leg muscle weakness/atrophy that suggested an inflammatory myopathy. The patient carried an 18p deletion, two potentially permissive 4qA alleles, and marked D4Z4 (sized … [Read more]

The institute will participate in the Science Fair on 13th & 14th October

For this new 2018 edition of the French science fair, “Fête de la Science”, researchers at the institute offer you to follow step by step the different techniques used to bring new knowledge on the field of muscle and to create the therapies of tomorrow. Where ? Village des Sciences Sorbonne Université 4 place Jussieu … [Read more]

A French first in cardiac surgery for Duchenne and Becker myopathies

A left ventricular assist device was implanted in two patients with myopathy (Duchenne and Becker), with refractory heart failure and not eligible at this stage for transplantation. In May 2018, Dr. Denis Duboc’s team implanted a left ventricular assist device in two patients, aged 20 and 40, with myopathy (Duchenne and Becker), refractory heart failure … [Read more]